QualityStocksNewsBreaks Archives - Page 640 of 1387

FridayMay 14, 2021 3:03 pm

QualityStocksNewsBreaks – Infobird Co. Ltd.’s (NASDAQ: IFBD) New SaaS Model Designed to Expand Customer Base, Capture More Market Share

Infobird (NASDAQ: IFBD), a leading artificial intelligence (“AI”) software-as-a-service (“SaaS”) provider is positioned for opportunity amid a wave of digital transformation sweeping across China. In the last two decades, the company has gleaned tremendous experience and achieved significant technological advances and service capabilities while providing customized SaaS products to some of China’s largest and most demanding financial institutions. With that solid foundation in place, Infobird recently implemented a strategic transition to standardized module SaaS with the intent to expand its customer base and quickly capture additional market share. “Standardized module SaaS has the characteristics of fast scale up and low…

FridayMay 14, 2021 2:06 pm

QualityStocksNewsBreaks – Wave Life Sciences Ltd. (NASDAQ: WVE) Featured in Mizuho Securities Research Report

Wave Life Sciences (NASDAQ: WVE) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “This morning, WVE held its 1Q21 call. We also had the opportunity to catch up with management post the call. The most important takeaway from today's call is that we now have a timeline as to when we can expect at least initial clinical data from Wave's new PN-chemistry based pipeline program(s) -- 2022. It's starting to set up as potentially as a really important year for the company in our view, if they produce multiple datasets, which…

FridayMay 14, 2021 1:39 pm

QualityStocksNewsBreaks – Healthtech Solutions Inc.’s (HLTT) Latest Acquisition Brings in Innovative Team of Experts

Healthtech Solutions (OTC: HLTT), focused on acquiring and investing in strategic cutting-edge health care technological opportunities, is among biotech players that have pivoted to a new model wherein multiple portfolio companies operate under one parent organization. Healthtech’s latest acquisition, Varian Biopharmaceuticals, brings to three the number of subsidiaries under its umbrella. “The acquisition of Varian by Healthtech plays to the strengths of the new portfolio model not only in drug pipeline but also by bringing in experts in an area that could attract additional investment,” reads a recent article. A precision oncology company, Varian specializes in developing atypical protein kinase…

FridayMay 14, 2021 1:33 pm

QualityStocksNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Focuses ‘Covid-ID Lab’ Commercialization Strategy Initially on German Market

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience technology accelerator, recently entered a strategic distribution, storage and logistics agreement for its commercial 25-minute COVID-19 RT-PCR test system (“Covid-ID Lab”). In April, XPhyto announced its entry into the agreement with a full-fledged German pharmaceutical wholesaler and service provider. Under the agreement, the German partner will distribute, store and deliver Covid-ID Lab test kits to XPhyto’s customers in line with product specifications and relevant logistical and regulatory requirements in Germany. A recent article quotes XPhyto CEO and Director Hugh Rogers, who noted that the company had secured a strong partner…

FridayMay 14, 2021 1:02 pm

QualityStocksNewsBreaks – Pac Roots Cannabis Corp. (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) Leverages Radically Different Cultivation Approach

Pac Roots (CSE: PACR) (OTCQB: PACRF) (FSE: 4XM) has sought to differentiate itself by focusing on a genetics-based cultivation approach that enables production of premium-quality strains and products. This focus is influenced by the company’s resolution to avoid the fate that has befallen its competitors that have seen recent declines in market share. According to a recent article, PACR’s genetics-based cultivation approach has allowed it “to produce 50 super-elite strains and roughly 350 tested cultivars, which in turn has resulted in the company maximizing yields, boosting profitability and minimizing labor costs. In fact, as Pac Roots CEO explained, the company’s…

FridayMay 14, 2021 12:37 pm

QualityStocksNewsBreaks – Brain Scientific Inc. (BRSF) Collaborating to Potentially Uncover Innovative New Treatment Options

Brain Scientific (OTCQB: BRSF), focused on modernizing the brain diagnostic market through cutting-edge technologies, recently began a collaboration with JelikaLite in a clinical trial. The clinical trial, which has 30 participants from two New York City locations, is designed to potentially uncover new treatment options to reduce autism symptoms in children. “JelikaLite was launched by medical researchers and practitioners specializing in psychology, neurology and phototherapy. The company has developed an innovative solution to potentially reduce autism symptoms and is developing a home-based system that combines a therapeutic wearable device called Cognilum(TM) with an AI-personalized platform. . . Cognilum delivers treatments…

FridayMay 14, 2021 12:24 pm

QualityStocksNewsBreaks – Hunter Technology Corp. (TSX.V: HOC) (OTCQB: HOILF) (WKN: A2QEYH) (FSE: RWPM) Announces May 17 Webcast

Hunter Technology (TSX.V: HOC) (OTCQB: HOILF) (WKN: A2QEYH) (FSE: RWPM), a developer of digital marketplaces for global energy trading, has scheduled a webcast to connect with shareholders, investors and analysts. Hunter CEO Florian M Spiegl will host the webcast, which is scheduled for Monday, May 17, 2021, at 4:30 p.m. ET. Interested parties are encouraged to participate in the call and also submit questions before the call for Hunter Technology management to answer. Those questions can be sent via email at ir@huntertechnology.com or upon registering for the call. To register for the call, visit https://ibn.fm/i9D58 To view the full press…

FridayMay 14, 2021 11:56 am

QualityStocksNewsBreaks – Knightscope Inc. Secures Additional $21.9M, Now Responsible for Two Largest Raises in StartEngine’s History

Knightscope, a developer of advanced physical security technologies utilizing fully autonomous security robots (“ASRs”), has successfully completed its most recent public offering, raising an additional $21.91 million. According to the update, Knightscope has now completed the two largest funding rounds in the history of the StartEngine platform. Knightscope has raised $90+ million from more than 28,000 investors and is poised to be an industry leader in the future of public safety and security. In addition, the company has reserved ticker symbol ‘KSCP’ with Nasdaq and is contemplating a possible public listing. “Knightscope’s long-term vision has an eye on the greater…

FridayMay 14, 2021 11:08 am

QualityStocksNewsBreaks – Nextech AR Solutions Corp. (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29) Designated as a Preferred Vendor by Visit Tampa Bay

Nextech (CSE: NTAR) (NEO: NTAR) (OTCQB: NEXCF) (FSE: N29), a leading provider of web-based augmented reality for e-commerce, advertising and virtual events, today announced a strategic partnership with Visit Tampa Bay. Designated as a preferred vendor by Visit Tampa Bay, the partnership affords the company the opportunity to connect with confirmed conferences for the city. Nextech is committed to building strategic partnerships with the world’s top destination marketing organizations and extending their reach through virtual and hybrid events. "We are thrilled to partner with Tampa Bay,” said Nextech CEO and Director Evan Gappelberg. “Nextech’s hybrid and virtual events platform keeps…

FridayMay 14, 2021 10:59 am

QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is funded and targeting major milestones throughout this year. Corporate highlights for the company included the selection of five clinical sites around the United States for the upcoming phase 2b randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of PCS499 in treating patients who…

Site Search

Company Search

Category: QualityStocksNewsBreaks